New treatments aiming to extend the time before menopause arrives are being developed and trialled, but some gynaecologists question whether these advances will change how menopause is managed. A year ago, at age 57, a woman learned from her gynaecologist Sara J Matthews at the HCA Portland Hospital that she had one egg left. The news prompted reflection on whether delaying the loss of eggs is beneficial and whether research is seeking to slow that process.
Trials and New Technologies
Columbia University in New York is trialling low-dose rapamycin, a transplant drug, in women aged 35-45 because it slowed ovarian ageing in mice. Preliminary data from the first 34 women suggests it may slow human ovarian ageing by about 20 per cent, with the next phase eventually enrolling 1,000 women.
Oviva Therapeutics has developed a protein based on anti-Müllerian hormone (AMH), the chemical that keeps eggs in reserve. The company's founder spoke of extending "the runway to menopause". Granata Bio bought the company last year and is pointing the drug first at IVF. Separately, Oura says more than 100,000 women are contributing to its perimenopause research.
A new wearable called Clair, due to ship in January, claims to track oestrogen, progesterone, LH (luteinising hormone) and FSH (follicle-stimulating hormone) continuously without a needle. LH and FSH tell the ovary to ripen and release an egg and tend to be used as menopause markers.
The Pharmaceutical Charge
In July 2025, the UK medicines regulator MHRA approved a drug called elinzanetant, sold as Lynkuet, before any other regulator in the world. It is a once-daily pill for hot flushes containing no hormone, working by blocking two neurokinin receptors in the hypothalamus, the brain's thermostat, which misfires when oestrogen falls. The science behind this class of drugs was done at Imperial College, where Professor Waljit Dhillo's team showed that injecting a brain peptide called neurokinin B into pre-menopausal women gave them hot flushes. Elinzanetant was a GlaxoSmithKline schizophrenia drug, abandoned in 2012 and rescued by former scientists working out of a business park in Stevenage. Bayer paid $425 million for it in 2020.
Professor Mary Ann Lumsden, who chaired the NICE menopause guidelines a decade ago and now sees patients at Hormone Health in Marylebone, thinks the drug is "fantastic" for women who cannot otherwise take HRT, including those with breast cancer, and it helps with sleep, though it is expensive and not widely available. "More lookalike [drugs] are coming," she says, while pointing out that it is too simplistic to assume that menopause has simply moved from the ovary to the brain.
"It's not just running out of oestrogen," she says, "it's the fluctuations." Australian research from the 1990s showed that in perimenopause, oestrogen and FSH "fluctuate by the second", which is why hormone testing in perimenopause is "a complete waste of time".
To Drug or Not to Drug
On rapamycin, Lumsden is cautious. "I suspect that it's clinical physiology," she says, the kind of research that matters in 20 years rather than two. On the AMH drug she is blunter — the hormone reflects the follicle pool, it does not protect it, and "it's not the eggs themselves that produce the oestrogen". What will change practice in the future, she thinks, is genomics: a personal estimate of risk, so that chances of getting breast cancer from HRT can be better predicted.
Dr Sabine Donnai, whose clinic Viavi offers extensive diagnostics in London, is cautiously optimistic about the menopausal future. A standard blood test, she agrees, "captures a moment in time". Her patients get imaging, metabolic testing, genetics and molecular markers because what interests her is not so much whether oestrogen is falling, but how a woman's body is coping with the fall. Continuous hormone data would be "fascinating", she says, but "measuring more doesn't necessarily mean understanding more".
Her 10-year vision is that menopause "will no longer come as a surprise". A woman of 38 will know her trajectory and act on her bones, heart and brain before a single symptom arrives.
As for whether a year of a personal hormone curve on a phone or wearable could change how doctors practise, Lumsden says probably not. She argues that the long chat will always be the most important part of any consultation. "People need to have time to see patients. I think in the future it may be something more multidisciplinary — menopause hubs, with psychologists and different specialties interacting. More emphasis on lifestyle: keeping people feeling well with exercise and diet."
On whether delaying the loss of eggs is a good thing, Lumsden looks to other cultures for inspiration, particularly South Asia where she has travelled extensively and marvels at how women age beautifully, "comfortable in their own skin". She points out that people will live into their eighties and nineties, and we still do not understand what hormones do to our brains. "We need to get people to cope with ageing better," she says. "We can't stay young forever."